Insights

Loading spinner
Gathering insights about Ability Pharmaceuticals, SA

Ability Pharmaceuticals, SA Tech Stack

Ability Pharmaceuticals, SA uses 8 technology products and services including Google Analytics, Font Awesome, FancyBox, and more. Explore Ability Pharmaceuticals, SA's tech stack below.

  • Google Analytics
    Analytics
  • Font Awesome
    Font Scripts
  • FancyBox
    Javascript Libraries
  • Google Maps
    Maps
  • Open Graph
    Miscellaneous
  • YouTube
    Video Players
  • Apache HTTP Server
    Web Servers
  • Apache
    Web Servers

Media & News

Ability Pharmaceuticals, SA's Email Address Formats

Ability Pharmaceuticals, SA uses at least 1 format(s):
Ability Pharmaceuticals, SA Email FormatsExamplePercentage
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
25%
First.Middle@abilitypharma.comJohn.Michael@abilitypharma.com
25%
First.Last@abilitypharma.comJohn.Doe@abilitypharma.com
25%
First.Middle@abilitypharma.comJohn.Michael@abilitypharma.com
25%

Frequently Asked Questions

Where is Ability Pharmaceuticals, SA's headquarters located?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SA's main headquarters is located at Avinguda Parc Tecnològic, 3 Cerdanyola del Vallès, Catalonia 08290 ES. The company has employees across 2 continents, including EuropeNorth America.

What is Ability Pharmaceuticals, SA's phone number?

Minus sign iconPlus sign icon
You can contact Ability Pharmaceuticals, SA's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Ability Pharmaceuticals, SA's official website and social media links?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SA's official website is abilitypharma.com and has social profiles on LinkedIn.

How much revenue does Ability Pharmaceuticals, SA generate?

Minus sign iconPlus sign icon
As of June 2024, Ability Pharmaceuticals, SA's annual revenue reached $3.8M.

What is Ability Pharmaceuticals, SA's SIC code NAICS code?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SA's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ability Pharmaceuticals, SA have currently?

Minus sign iconPlus sign icon
As of June 2024, Ability Pharmaceuticals, SA has approximately 22 employees across 2 continents, including EuropeNorth America. Key team members include Chief Business Officer: D. S.Chief Operating Officer: H. P. M.Head Of Operations & Translational Research: M. Y. V.. Explore Ability Pharmaceuticals, SA's employee directory with LeadIQ.

What industry does Ability Pharmaceuticals, SA belong to?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SA operates in the Biotechnology Research industry.

What technology does Ability Pharmaceuticals, SA use?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SA's tech stack includes Google AnalyticsFont AwesomeFancyBoxGoogle MapsOpen GraphYouTubeApache HTTP ServerApache.

What is Ability Pharmaceuticals, SA's email format?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SA's email format typically follows the pattern of . Find more Ability Pharmaceuticals, SA email formats with LeadIQ.

How much funding has Ability Pharmaceuticals, SA raised to date?

Minus sign iconPlus sign icon
As of June 2024, Ability Pharmaceuticals, SA has raised $7.7M in funding. The last funding round occurred on Mar 11, 2024 for $7.7M.

When was Ability Pharmaceuticals, SA founded?

Minus sign iconPlus sign icon
Ability Pharmaceuticals, SA was founded in 2009.
Ability Pharmaceuticals, SA

Ability Pharmaceuticals, SA

Biotechnology ResearchCatalonia, Spain11-50 Employees

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. 

AbilityPharma's is currently conducting, with ABTL0812, the most advanced asset, an international multi-center, double-blind, placebo-controlled phase 2b clinical trial in patients with metastatic pancreatic cancer to investigate ABTL0812 as first-lin therapy in combination with FOLFIRINOX chemotherapy. The study includes reference centers in Spain, France, United States and Israel.

ABTL0812  has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard).

ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound has also immunomodulatory effects, turning "cold" immunogenic tumors into "hot" immunogenic.

The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. 

ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. 

Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc.

Section iconCompany Overview

Headquarters
Avinguda Parc Tecnològic, 3 Cerdanyola del Vallès, Catalonia 08290 ES
Phone number
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
11-50

Section iconFunding & Financials

  • $7.7M

    Ability Pharmaceuticals, SA has raised a total of $7.7M of funding over 9 rounds. Their latest funding round was raised on Mar 11, 2024 in the amount of $7.7M.

  • $10M

    Ability Pharmaceuticals, SA's revenue is in the range of $10M

Section iconFunding & Financials

  • $7.7M

    Ability Pharmaceuticals, SA has raised a total of $7.7M of funding over 9 rounds. Their latest funding round was raised on Mar 11, 2024 in the amount of $7.7M.

  • $10M

    Ability Pharmaceuticals, SA's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.